List of Excipients in Branded Drug AMANTADINE

« Back to Dashboard

Generic Drugs Containing AMANTADINE

Company	Ingredient	NDC	Excipient
Xttrium Laboratories Inc	amantadine	0116-4010	ANHYDROUS CITRIC ACID
Xttrium Laboratories Inc	amantadine	0116-4010	METHYLPARABEN
Xttrium Laboratories Inc	amantadine	0116-4010	PROPYLENE GLYCOL
Xttrium Laboratories Inc	amantadine	0116-4010	PROPYLPARABEN
Xttrium Laboratories Inc	amantadine	0116-4010	SACCHARIN SODIUM
Xttrium Laboratories Inc	amantadine	0116-4010	SORBITOL

What are the Most Frequently-Used Excipients in AMANTADINE?

# Of NDCs	Excipient
2	ANHYDROUS CITRIC ACID
8	CELLULOSE, MICROCRYSTALLINE
3	CROSCARMELLOSE SODIUM
3	FD&C BLUE NO. 1
3	FD&C RED NO. 40
5	FD&C YELLOW NO. 6

Amantadine Excipient Strategy and Commercial Opportunities

Last updated: October 30, 2026

Amantadine is a mature generic active pharmaceutical ingredient with two distinct commercial platforms: low-cost immediate-release products and differentiated extended-release products for Parkinson's disease and levodopa-induced dyskinesia. The strongest excipient opportunities are in modified release, taste and swallowability, renal-risk reduction, pediatric or geriatric administration, and manufacturing-cost optimization.

The active ingredient is usually amantadine hydrochloride. Immediate-release tablets and capsules compete primarily on price. Gocovri and Osmolex ER compete through delivery technology, dosing convenience, and disease-specific labeling rather than through novel chemistry. Excipient selection therefore has direct commercial value when it supports release control, dose flexibility, stability, capsule or tablet performance, and regulatory differentiation.

What dosage forms and excipient systems are used for amantadine?

Amantadine products fall into four practical formulation categories.

Product category	Typical dosage form	Primary commercial objective	Excipient priorities
Generic immediate-release	100 mg tablet or capsule	Lowest cost and broad substitution	Compressibility, stability, low manufacturing cost
Oral solution or liquid	Solution or suspension	Swallowing access and dose flexibility	Solubility, preservative system, taste masking
Gocovri	Extended-release capsule	Bedtime dosing and dyskinesia control	Multiparticulate release, capsule fill, moisture protection
Osmolex ER	Extended-release tablet	Once-daily Parkinson's and drug-induced extrapyramidal symptom treatment	Matrix or controlled-release architecture, tablet robustness, dose proportionality

The immediate-release product has a comparatively simple excipient strategy. Common platform materials include microcrystalline cellulose, lactose or other diluents, starch, povidone, crospovidone, colloidal silicon dioxide, talc, and magnesium stearate. Exact compositions vary by manufacturer and dosage form and must be confirmed against the applicable product label and regulatory filing.

Extended-release products require a more defensible formulation architecture. The commercial value is created by controlling the rate and location of amantadine release while maintaining dose uniformity and acceptable capsule or tablet performance.

Which excipients are commercially important for amantadine extended release?

Release-controlling polymers

Hydrophilic polymers such as hydroxypropyl methylcellulose can form a hydrated matrix that controls drug diffusion and erosion. Ethylcellulose and related insoluble polymers can provide stronger release barriers in coated pellets or multiparticulate systems.

The selection affects:

• Twelve- to 24-hour release performance
• Food-effect sensitivity
• Dose dumping risk
• Tablet size
• Manufacturing throughput
• Alcohol-induced release behavior
• Bioequivalence against the reference product

Multiparticulate systems can reduce the impact of local gastrointestinal conditions because the dose is distributed across many particles. They also allow coating thickness and polymer composition to be tuned with greater precision than a single monolithic tablet.

Pellet and coating excipients

A pelletized product may use sugar spheres or inert cores, binders, drug-layering materials, pore formers, and polymer coatings. Common functional categories include:

• Microcrystalline cellulose cores
• Povidone or hydroxypropyl cellulose as a binder
• Ethylcellulose for sustained release
• Hypromellose as a seal coat or pore-forming layer
• Talc or colloidal silicon dioxide as anti-tacking agents
• Triethyl citrate or similar plasticizers

For a developer seeking a differentiated amantadine product, the coating process may be more important than the identity of any individual excipient. Uniform coating, low agglomeration, and reproducible residual solvent levels can determine whether a product achieves acceptable dissolution and scale-up performance.

Matrix-tablet excipients

A once-daily tablet can use a hydrophilic matrix, insoluble matrix, or osmotic architecture. The principal excipient variables are polymer grade, viscosity, particle size, compression force, and tablet porosity.

A matrix strategy generally offers lower manufacturing complexity than coated pellets. Its disadvantages can include greater sensitivity to tablet geometry, compression conditions, food intake, and alcohol exposure. A controlled-release tablet must also demonstrate mechanical integrity during packaging, transport, and gastrointestinal residence.

Lubricants and glidants

Magnesium stearate, stearic acid, colloidal silicon dioxide, and talc can improve processing, but excessive lubricant levels may reduce tablet hardness, slow wetting, or alter dissolution. For amantadine, this is commercially relevant because a low-dose formulation can be sensitive to segregation and content-uniformity problems.

A robust formulation should control:

• Lubricant mixing time
• Shear exposure
• Blend segregation
• Tablet tensile strength
• Friability
• Dissolution after accelerated storage

What formulation opportunities exist for generic amantadine?

The largest opportunity is not another conventional 100 mg tablet. That market is mature and price-sensitive. More attractive opportunities involve patient access, administration convenience, and differentiated release profiles.

Sprinkleable extended-release capsules

A capsule that can be opened and sprinkled onto soft food may address patients with dysphagia, Parkinson's-related motor impairment, or difficulty swallowing tablets. The commercial design must preserve pellet integrity. Crushing, chewing, or prolonged exposure to food moisture cannot cause rapid release.

Relevant excipient work includes:

• Polymer coating resistant to mechanical damage
• Low-moisture capsule fill
• Improved pellet flow
• Taste masking
• Food compatibility
• Reproducible dose recovery after sprinkling

Taste-masked oral liquid

Amantadine hydrochloride is highly water soluble, which supports liquid development but creates taste challenges. A liquid product could target pediatric use, patients with dysphagia, and institutional settings.

Commercially useful strategies include:

• Ion-exchange resin complexes
• Cyclodextrin complexes
• Polymer taste barriers
• Sweetener and flavor systems
• Buffered pH control
• Preservative systems compatible with the active ingredient

A suspension may provide greater taste-masking flexibility than a solution, but it creates settling, redispersibility, dose-uniformity, and microbial-control requirements.

Orally disintegrating tablets

An orally disintegrating tablet could improve administration for patients who cannot swallow conventional tablets. The formulation would require rapid wetting and disintegration without producing an unacceptable bitter taste.

Potential excipients include crospovidone, croscarmellose sodium, mannitol, low-substituted hydroxypropyl cellulose, and taste-masking polymers. The principal commercial barriers are dose size, friability, packaging moisture sensitivity, and the need to prevent premature release if a modified-release claim is pursued.

Smaller-dose strengths

Amantadine is substantially cleared by the kidneys, and renal impairment can increase exposure. Geriatric patients are especially relevant because Parkinson's disease prevalence rises with age. Lower-strength tablets or scored dosage forms can support titration and renal dosing.

Dose flexibility can be created through:

• 25 mg or 50 mg immediate-release units
• Scored 100 mg tablets
• Multi-unit pellet capsules
• Liquid dosing
• Combination packaging for titration schedules

A lower-dose product may have a modest unit price but can improve formulary access and prescriber adoption.

How does amantadine renal clearance affect excipient strategy?

Renal elimination is a central product-design constraint. The formulation cannot eliminate the need for dose adjustment in renal impairment, but it can improve dose control and reduce administration errors.

The strongest design responses are:

1. Multiple low-dose strengths.
2. Clearly graduated liquid dosing.
3. Consistent release across fed and fasted conditions.
4. Avoidance of unnecessary excipients that complicate tolerability in older patients.
5. Packaging that reduces medication-selection errors.

Amantadine products may be associated with central nervous system adverse effects, including confusion, hallucinations, dizziness, and insomnia. Excipient strategy cannot remove these pharmacologic risks, but predictable exposure can be commercially important when competing against less controlled generic formulations.

What FDA regulatory status applies to amantadine products?

Immediate-release amantadine hydrochloride products are generally approved through abbreviated new drug applications when they demonstrate pharmaceutical equivalence and bioequivalence to the reference product. The FDA-approved uses historically include Parkinson's disease and drug-induced extrapyramidal reactions. The influenza indication has diminished commercial relevance because of widespread resistance among circulating influenza A viruses and current public-health treatment practice.

Gocovri is an extended-release amantadine product approved for dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic therapy. It is also approved for Parkinson's disease patients receiving levodopa-based therapy with or without concomitant dopaminergic therapy.[1]

Osmolex ER is an extended-release amantadine product approved for Parkinson's disease and drug-induced extrapyramidal reactions in adults.[2]

For a generic ER entrant, the regulatory route may involve:

• Paragraph IV certification against listed patents
• A suitability petition if seeking a different strength or dosage form
• A 505(b)(2) application for a clinically or technically differentiated formulation
• Comparative bioavailability or bioequivalence studies
• Fed and fasted pharmacokinetic testing
• In vitro abuse of release, alcohol-dose-dumping, and dissolution testing where applicable

What is the Orange Book status of amantadine products?

The Orange Book distinguishes between the mature immediate-release market and branded extended-release products. Immediate-release amantadine products generally have limited formulation differentiation and face conventional ANDA competition. Branded ER products may have listed patents covering formulation, release profile, dosage regimen, or method of use.

The commercial implications are different:

Product type	Orange Book and litigation exposure	Generic-entry profile
Immediate-release amantadine	Usually limited patent friction	Multiple manufacturers and rapid price erosion
Gocovri	Formulation and method-of-use patent exposure may be material	Requires careful patent certification and bioequivalence strategy
Osmolex ER	ER formulation and product-specific patent review required	Greater technical barrier than IR tablets
New liquid or ODT product	May rely on new formulation claims	Potential 505(b)(2) or differentiated generic strategy

Patent status changes as patents expire, are delisted, are challenged, or are affected by litigation and settlement. Current Orange Book entries and FDA patent-list records should control any launch decision.[3] Patent numbers, expiration dates, and litigation positions should not be inferred from the active ingredient's age.

When does amantadine lose exclusivity?

The active ingredient itself has long lost basic composition-of-matter exclusivity. Commercial exclusivity now depends on product-specific formulation, method-of-use, regulatory, and manufacturing rights.

Exclusivity layer	Current business significance
Amantadine molecule	No meaningful new-molecule barrier
Immediate-release dosage form	Low barrier; price competition dominates
Gocovri extended-release formulation	Product-specific patent and regulatory review required
Osmolex ER extended-release formulation	Product-specific patent and bioequivalence barrier required
Orphan or pediatric protections	Must be confirmed product by product
Manufacturing know-how	Can delay practical competition even after patent expiry

A generic company can face a launch gap between legal eligibility and commercial readiness. Scale-up, dissolution matching, stability, packaging, and FDA review can be more important than the remaining patent term for a technically complex ER product.

Which companies are challenging branded amantadine products?

The immediate-release market includes multiple generic manufacturers and contract manufacturers. Branded extended-release products have been commercialized by companies including Adamas Pharmaceuticals and Supernus Pharmaceuticals. Supernus acquired Adamas in 2021, bringing Gocovri into the Supernus portfolio.[4]

The competitive landscape has three groups:

1. Commodity generic manufacturers selling immediate-release products.
2. Specialty pharmaceutical companies commercializing ER products.
3. Formulation developers targeting alternative delivery systems, lower strengths, liquids, and sprinkle products.

Publicly identifying a specific Paragraph IV challenger requires confirmation from FDA filings, court dockets, or company disclosures. The relevant competitive signal is an ANDA filing with a patent certification, not a generic product listing alone.

What patent litigation and settlement issues affect amantadine?

The principal litigation risks are likely to arise around extended-release formulation claims, dissolution profiles, pellet architecture, dosing regimens, and method-of-use claims for dyskinesia or Parkinson's disease.

A challenger should assess:

• Whether the asserted claims require a specific polymer or coating architecture
• Whether bioequivalence can be shown without reproducing the claimed formulation
• Whether a design-around changes food effect or release kinetics
• Whether a Paragraph IV notice triggers a 30-month stay
• Whether a settlement provides a licensed entry date
• Whether claims survive inter partes review or district-court review
• Whether the product is subject to pediatric, regulatory, or market exclusivity

Settlement agreements can create an earlier authorized-generic or licensed-generic entry date. Their economic value depends on volume restrictions, royalty obligations, launch timing, and whether the branded company retains an authorized generic position.

How strong is the amantadine patent estate?

The patent estate is weak for the active ingredient and conventional immediate-release products. It is materially stronger for proprietary ER formulations where release control, dosing time, and clinical use are linked.

Estate segment	Relative strength	Reason
Basic amantadine composition	Low	Mature molecule
Standard 100 mg tablet	Low	Established manufacturing and broad generic substitution
Taste-masked liquid	Moderate	Formulation and sensory claims may be available
ODT or sprinkle product	Moderate	Device, excipient, and administration claims can create barriers
ER multiparticulate capsule	Moderate to high	Manufacturing and release-profile complexity
ER method of use	Moderate	Clinical and dosing claims may remain relevant
API manufacturing process	Moderate	DMF, impurity control, and supply qualification can matter

The strongest defensible position is usually a combination of formulation claims, process controls, product-specific dissolution specifications, and clinical labeling. A single excipient claim is less durable than a patent family covering composition, manufacturing, and use.

What commercial opportunities exist for amantadine excipients?

Excipient suppliers and formulation developers can pursue four practical opportunities.

1. Controlled-release platforms

A polymer system that reliably produces once-daily amantadine release across manufacturing scales could support licensing to generic or specialty companies. The value proposition is reduced formulation-development time and a lower risk of failed bioequivalence studies.

2. Low-cost pellet technology

A simplified multiparticulate process using commercially available polymers and high-throughput coating equipment could support an ER generic with lower cost of goods than a complex reference formulation.

3. Taste-masking systems

An excipient platform that masks amantadine bitterness without impairing dissolution could support liquids, ODTs, and sprinkle capsules. The most attractive target populations are older adults, dysphagia patients, and institutional-care users.

4. Excipient systems for renal-dose flexibility

A portfolio of low-dose tablets or a calibrated liquid can address the clinical need for dose adjustment. Packaging, measuring devices, and human-factors design can add commercial differentiation even when the formulation itself is not highly novel.

How does amantadine compare with other Parkinson's disease formulation opportunities?

Amantadine is less attractive than levodopa or dopamine agonists for absolute market size, but it offers a lower development burden and a clearer formulation niche.

Drug	Formulation opportunity	Competitive barrier	Market logic
Amantadine	ER, liquid, ODT, sprinkle	Moderate	Mature API with specialized delivery gaps
Levodopa/carbidopa	ER, intestinal gel, inhaled and oral systems	High	Large market but crowded and clinically complex
Pramipexole	ER and IR	Moderate	Established generic competition
Ropinirole	ER and IR	Moderate	Generic price pressure
Safinamide	Specialty oral formulations	Higher	Newer product and stronger branded positioning

Amantadine is best suited to a focused formulation program rather than a broad primary-care generic strategy.

Key Takeaways

• Immediate-release amantadine is a low-margin generic market with limited excipient differentiation.
• Extended-release formulations provide the most valuable commercial and patent opportunity.
• Gocovri and Osmolex ER represent distinct reference-product targets and require separate regulatory and patent strategies.
• Pellet coatings, matrix polymers, taste-masking systems, and low-dose presentations are the most relevant excipient platforms.
• Renal clearance makes dose flexibility and predictable exposure important design objectives.
• The active ingredient has no meaningful composition-of-matter exclusivity; competitive protection comes from formulation, method of use, process, and regulatory rights.
• A differentiated liquid, ODT, sprinkle capsule, or lower-strength product may support a 505(b)(2), specialty generic, or licensing strategy.
• Orange Book listings, FDA labels, patent certifications, and court records should control launch timing and freedom-to-operate conclusions.

FAQs

Is amantadine suitable for a new extended-release generic?

Yes. The opportunity is technically viable but requires careful matching of dissolution, food effect, dose proportionality, and pharmacokinetics. The commercial case is stronger for a lower-cost ER product than for another conventional immediate-release tablet.

Which excipient is best for extended-release amantadine?

No single excipient is universally best. Hypromellose matrices, ethylcellulose coatings, multiparticulate systems, and osmotic architectures each offer different control over release, manufacturing complexity, and bioequivalence risk.

Can amantadine be developed as an oral liquid?

Yes. Amantadine hydrochloride's water solubility supports liquid development, but bitterness, preservative compatibility, dose uniformity, and stability require dedicated formulation work.

Does amantadine have biosimilar competition?

No. Amantadine is a small-molecule drug, so competition proceeds through generic, hybrid, or reformulated-product pathways rather than the biosimilar pathway.

What is the most attractive commercial niche for amantadine?

A technically robust, once-daily or sprinkleable extended-release product with lower-dose flexibility is the strongest niche. It addresses administration and dosing problems that conventional 100 mg generic tablets do not solve.

References

1. U.S. Food and Drug Administration. (2024). Gocovri (amantadine) extended-release capsules: Prescribing information.
2. U.S. Food and Drug Administration. (2024). Osmolex ER (amantadine) extended-release tablets: Prescribing information.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. Supernus Pharmaceuticals, Inc. (2021). Supernus Pharmaceuticals completes acquisition of Adamas Pharmaceuticals.
5. U.S. National Library of Medicine. (2024). DailyMed: Amantadine hydrochloride products.
6. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary.